# Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

> **NCT06969807** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Kidney Disease (DKD)

## Interventions

- **DRUG:** Amimestrocel

## Key facts

- **NCT ID:** NCT06969807
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2026-05-15
- **Final completion:** 2028-05-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969807, "Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06969807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*